Vascularization in skin wound healing: where do we stand and where do we go

被引:61
|
作者
Moreira, Helena R. [1 ,2 ,3 ]
Marques, Alexandra P. [1 ,2 ,3 ]
机构
[1] Univ Minho, 3Bs Res Grp, I3Bs Res Inst Biomat Biodegradables & Biomimet, Avepark Zona Ind,Gandra, P-4805017 Guimara, Portugal
[2] European Inst Excellence Tissue Engn & Regenerat, Avepark Zona Ind,Gandra, P-4805017 Guimara, Portugal
[3] ICVS 3Bs PT Govt Associate Lab, P-4805017 Braga, Guimaraes, Portugal
基金
欧洲研究理事会;
关键词
ENDOTHELIAL GROWTH-FACTOR; SPONGY-LIKE HYDROGELS; DERMAL FIBROBLASTS; ANGIOGENESIS; CELLS; MORPHOGENESIS; INFLAMMATION; ACTIVATION; CHALLENGES; INDUCTION;
D O I
10.1016/j.copbio.2021.08.019
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Cutaneous healing is a highly complex process that, if altered due to, for example, impaired vascularization, results in chronic wounds or repaired neotissue of poor quality. Significant progress has been achieved in promoting neotissue vascularization during tissue repair/regeneration. In this review, we discuss the strategies that have been explored and how each one of them contributes to regulate vascularization in the context of cutaneous wound healing from two different perspectives - biomaterial-based and a cell-based approaches. Finally, we discuss the implications of these findings on the development of the 'next generation' approaches to target vascularization in wound healing highlighting the importance of going beyond its contribution to regulate vascularization and take into consideration the temporal features of the healing process and of different types of wounds.
引用
收藏
页码:253 / 262
页数:10
相关论文
共 50 条
  • [1] Gephyrin: where do we stand, where do we go?
    Fritschy, Jean-Marc
    Harvey, Robert J.
    Schwarz, Guenter
    TRENDS IN NEUROSCIENCES, 2008, 31 (05) : 257 - 264
  • [2] ColVI myopathies: where do we stand, where do we go?
    Allamand, Valerie
    Brinas, Laura
    Richard, Pascale
    Stojkovic, Tanya
    Quijano-Roy, Susana
    Bonne, Gisele
    SKELETAL MUSCLE, 2011, 1
  • [3] Investigative dermatology: where do we stand and where do we go?
    Maurer, M.
    von Stebut, E.
    EXPERIMENTAL DERMATOLOGY, 2010, 19 (10) : 857 - 857
  • [4] Rye and health - Where do we stand and where do we go?
    Jonsson, Karin
    Andersson, Roger
    Knudsen, Knud Erik Bach
    Hallmans, Goran
    Hanhineva, Kati
    Katina, Kati
    Kolehmainen, Marjukka
    Kyro, Cecilie
    Langton, Maud
    Nordlund, Emilia
    Laerke, Helle Nygaard
    Olsen, Anja
    Poutanen, Kajsa
    Tjonneland, Anne
    Landberg, Rikard
    TRENDS IN FOOD SCIENCE & TECHNOLOGY, 2018, 79 : 78 - 87
  • [5] ColVI myopathies: where do we stand, where do we go?
    Valérie Allamand
    Laura Briñas
    Pascale Richard
    Tanya Stojkovic
    Susana Quijano-Roy
    Gisèle Bonne
    Skeletal Muscle, 1
  • [6] Treatment of negative symptoms: Where do we stand, and where do we go?
    Aleman, Andre
    Lincoln, Tania M.
    Bruggeman, Richard
    Melle, Ingrid
    Arends, Johan
    Arango, Celso
    Knegtering, Henderikus
    SCHIZOPHRENIA RESEARCH, 2017, 186 : 55 - 62
  • [7] Where do we stand on neuroprotection? Where do we go from here?
    Shoulson, I
    MOVEMENT DISORDERS, 1998, 13 : 46 - 48
  • [8] THE CYTOGENETICS OF RENAL TUMORS - WHERE DO WE STAND, WHERE DO WE GO
    WALTER, TA
    BERGER, CS
    SANDBERG, AA
    CANCER GENETICS AND CYTOGENETICS, 1989, 43 (01) : 15 - 34
  • [9] THE DECADE OF TOTAL QUALITY - WHERE DO WE STAND - WHERE DO WE GO
    YEAGER, R
    PIMA MAGAZINE, 1994, 76 (03): : S2 - S3
  • [10] Occupational Rhinitis and Asthma: Where Do We Stand, Where Do We Go?
    Castano, Roberto
    Malo, Jean-Luc
    CURRENT ALLERGY AND ASTHMA REPORTS, 2010, 10 (02) : 135 - 142